(RTTNews) - CSL (CSL.AX) and Alentis Therapeutics have entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class therapy targeting claudin-1 for the treatment of rare kidney, liver and other diseases, CSL said in a
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.